Related Experiment Video
Updated: Jul 6, 2026
Comprehensive Evaluation of the Effectiveness and Safety of Placenta-Targeted Drug Delivery Using Three Complementary Methods
Published on: September 10, 2018
sFlt-1/PlGF Ratio in the Diagnosis of Preeclampsia on the MAGLUMI X3 Analyzer
Pavel Broz1,2, Simona Kukralova1,2, Zdenek Sebesta1
1Institute of Clinical Biochemistry and Hematology, University Hospital in Pilsen, Pilsen, Czech Republic.
We compared the analytical and clinical performance of MAGLUMI X3 (Snibe) and Elecsys (Roche) for measuring sFlt-1, PlGF, and their ratio in women hospitalized at the Department of Gynecology and Obstetrics, University Hospital in Pilsen. In a single-center, real-world cohort (192 samples from 164 patients), method comparison showed good agreement between analyzers. Diagnostic discrimination for preeclampsia (PE vs. non-PE) was similar across platforms (AUC early-onset 0.84-0.85; late-onset 0.95 each; no significant difference by DeLong).
We compared the analytical and clinical performance of MAGLUMI X3 (Snibe) and Elecsys (Roche) for measuring sFlt-1, PlGF, and their ratio in women hospitalized at the Department of Gynecology and Obstetrics, University Hospital in Pilsen. In a single-center, real-world cohort (192 samples from 164 patients), method comparison showed good agreement between analyzers. Diagnostic discrimination for preeclampsia (PE vs. non-PE) was similar across platforms (AUC early-onset 0.84-0.85; late-onset 0.95 each; no significant difference by DeLong).